Brandy Fidler

Meghna Misra of Claritas Rx explains why billions in data infrastructure haven't stopped patient abandonment and what needs to change now.

Louis Cicchini, senior director of scientific affairs and strategic partnerships for cell & gene therapy at Cencora, discusses the reimbursement challenges threatening patient access to cell and gene therapies.

Industry experts reveal the sophisticated approaches needed to value contingent payments in life sciences M&A, and the costly mistakes companies often make. At a Glance Development milestones are binary events while commercial milestones introduce decades of uncertainty. Volatility is often underestimated when companies use larger public firms as comparable benchmarks. Synergies impact contingent consideration differently than acquired intangible asset valuations.